{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T01:37:33Z","timestamp":1774489053287,"version":"3.50.1"},"reference-count":27,"publisher":"Wiley","issue":"13","license":[{"start":{"date-parts":[[2019,8,22]],"date-time":"2019-08-22T00:00:00Z","timestamp":1566432000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Cancer Medicine"],"published-print":{"date-parts":[[2019,10]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Inotuzumab Ozogamicin (INO), has demonstrated an improvement in overall survival, high rate of complete remission, favorable patient\u2010reported outcomes, and manageable safety profile vs standard of care (SoC; intensive chemotherapy) for relapsed\/refractory (R\/R) acute lymphoblastic leukemia (ALL) in the phase 3 INO\u2010VATE trial. With a one\u2010hour weekly dosing schedule, INO might be associated with lower healthcare system burden. This study analyses hospitalizations for INO vs SoC.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>All patients receiving study treatment in the INO\u2010VATE trial were included. The days hospitalized during study treatment was calculated. Due to different treatment durations for INO and SoC (median of 3 vs 1 cycles), number of hospital days was mainly reported per observed patient month. Hospital days per patient month were analyzed for different treatment cycles, subgroups, and main reasons for hospitalization. Differences between treatments were analyzed by the incidence rate ratio (IRR).<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Overall, 82.9% and 94.4% INO and SoC patients experienced at least one hospitalization. The mean hospitalization days per patient month was 7.6 and 18.4\u00a0days for INO and SoC (IRR\u00a0=\u00a00.413, <jats:italic>P<\/jats:italic>\u00a0&lt;\u00a0.001), which corresponds to patients spending 25.0% and 60.5% of their treatment time in a hospital. Main hospitalization reasons were R\/R ALL treatment (5.2 (INO) vs 14.0 (SoC) days, IRR\u00a0=\u00a00.368, <jats:italic>P<\/jats:italic>\u00a0&lt;\u00a0.001), treatment toxicities (1.4 vs 2.8\u00a0days, IRR\u00a0=\u00a00.516, <jats:italic>P<\/jats:italic>\u00a0&lt;\u00a0.001) or other reasons (1.0 vs 1.6\u00a0days, IRR 0.629, <jats:italic>P<\/jats:italic>\u00a0&lt;\u00a0.001).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Inotuzumab Ozogamicin treatment in R\/R ALL is associated with a lower hospitalization burden compared with SoC. It is likely this lower burden has a favorable impact on healthcare budgets and cost\u2010effectiveness considerations.<\/jats:p><\/jats:sec>","DOI":"10.1002\/cam4.2480","type":"journal-article","created":{"date-parts":[[2019,8,22]],"date-time":"2019-08-22T12:04:31Z","timestamp":1566475471000},"page":"5959-5968","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Burden of hospitalization in acute lymphoblastic leukemia patients treated with Inotuzumab Ozogamicin versus standard chemotherapy treatment"],"prefix":"10.1002","volume":"8","author":[{"given":"David I.","family":"Marks","sequence":"first","affiliation":[{"name":"Bristol Haematology and Oncology Centre University Hospitals Bristol NHS Foundation Trust Bristol UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4944-5927","authenticated-orcid":false,"given":"Ilse","family":"van Oostrum","sequence":"additional","affiliation":[{"name":"Ingress\u2010Health Nederland B.V. Rotterdam The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sabrina","family":"Mueller","sequence":"additional","affiliation":[{"name":"Ingress\u2010Health HWM GmbH Wismar Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Verna","family":"Welch","sequence":"additional","affiliation":[{"name":"Pfizer Global HEOR New York NY USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Erik","family":"Vandendries","sequence":"additional","affiliation":[{"name":"Pfizer Inc Cambridge MA USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fausto R.","family":"Loberiza","sequence":"additional","affiliation":[{"name":"Pfizer Inc, Pharma GmbH Berlin Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sarah","family":"B\u00f6hme","sequence":"additional","affiliation":[{"name":"Pfizer Deutschland GmbH Berlin Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yun","family":"Su","sequence":"additional","affiliation":[{"name":"Independent Bridgewater NJ USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthias","family":"Stelljes","sequence":"additional","affiliation":[{"name":"Universit\u00e4tsklinikum M\u00fcnster M\u00fcnster Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1908-3307","authenticated-orcid":false,"given":"Hagop M.","family":"Kantarjian","sequence":"additional","affiliation":[{"name":"University of Texas MD Anderson Cancer Center Houston TX USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2019,8,22]]},"reference":[{"key":"e_1_2_7_2_1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21254"},{"key":"e_1_2_7_3_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-04-1623"},{"key":"e_1_2_7_4_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-10-116582"},{"key":"e_1_2_7_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0889-8588(05)70188-X"},{"key":"e_1_2_7_6_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.20668"},{"key":"e_1_2_7_7_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2004.10.050"},{"key":"e_1_2_7_8_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2402526"},{"key":"e_1_2_7_9_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V99.3.863"},{"key":"e_1_2_7_10_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V85.8.2025.bloodjournal8582025"},{"key":"e_1_2_7_11_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-12-399287"},{"key":"e_1_2_7_12_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2404824"},{"key":"e_1_2_7_13_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-08-234492"},{"key":"e_1_2_7_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0889-8588(05)70204-5"},{"key":"e_1_2_7_15_1","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-0142(19991001)86:7<1216::AID-CNCR17>3.0.CO;2-O"},{"key":"e_1_2_7_16_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.23919"},{"key":"e_1_2_7_17_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1509277"},{"key":"e_1_2_7_18_1","doi-asserted-by":"publisher","DOI":"10.1185\/03007995.2016.1164677"},{"key":"e_1_2_7_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2016.09.2171"},{"key":"e_1_2_7_20_1","doi-asserted-by":"publisher","DOI":"10.1080\/17843286.2017.1314091"},{"key":"e_1_2_7_21_1","doi-asserted-by":"publisher","DOI":"10.1080\/13696998.2016.1192549"},{"key":"e_1_2_7_22_1","doi-asserted-by":"publisher","DOI":"10.1093\/acprof:oso\/9780195172805.001.0001"},{"key":"e_1_2_7_23_1","volume-title":"Regression analysis of count data","author":"Colin CA","year":"2013"},{"key":"e_1_2_7_24_1","volume-title":"Introduction to mathematical sociology","author":"Coleman JS","year":"1964"},{"key":"e_1_2_7_25_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.35.15_suppl.e18500"},{"key":"e_1_2_7_26_1","first-page":"S1","article-title":"Hospitalization for patients treated with Inotuzumab Ozogamicin (InO) vs standard of care (SOC) for relapsed\/refractory acute lymphoblastic leukemia (ALL) in a global phase 3 randomized controlled trial (RCT)","volume":"23","author":"Kantarjian H","year":"2017","journal-title":"AMCP J Manag Care Spec Pharm"},{"key":"e_1_2_7_27_1","unstructured":"Scottish Medicines Consortium.Inotuzumab ozogamicin 1mg powder for concentrate for solution for infusion (BESPONSA\u00ae).2018;1328:1\u201015.https:\/\/www.scottishmedicines.org.uk\/media\/3469\/inotuzumab-ozogamicin-besponsa-final-may-2018-for-website.pdf. Accessed January 04 2019."},{"key":"e_1_2_7_28_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.31317"}],"container-title":["Cancer Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fcam4.2480","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cam4.2480","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/cam4.2480","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cam4.2480","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,8]],"date-time":"2023-09-08T20:45:56Z","timestamp":1694205956000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/cam4.2480"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,8,22]]},"references-count":27,"journal-issue":{"issue":"13","published-print":{"date-parts":[[2019,10]]}},"alternative-id":["10.1002\/cam4.2480"],"URL":"https:\/\/doi.org\/10.1002\/cam4.2480","archive":["Portico"],"relation":{},"ISSN":["2045-7634","2045-7634"],"issn-type":[{"value":"2045-7634","type":"print"},{"value":"2045-7634","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,8,22]]},"assertion":[{"value":"2019-05-08","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-07-25","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-08-22","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}